Amundi Denali Therapeutics Inc. Transaction History

Amundi

$275 Billion
Q4 2024

A detailed history of Amundi transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Amundi holds 85 shares of DNLI stock, worth $1,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$1,762

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 07, 2025	BUY	$20.24 - $31.58 $1,720 - $2,684	85 New	85 $1,000
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $151,755 - $236,653	3,017 New	3,017 $237,000

Others Institutions Holding DNLI

# of Institutions

241

Shares Held

121M

Call Options Held

80K

Put Options Held

36.8K

Black Rock Inc. New York, NY

13.2M
Shares

$273 Million
0.01% of portfolio
Baillie Gifford & CO

12.3M
Shares

$255 Million
0.2% of portfolio
Vanguard Group Inc Valley Forge, PA

12M
Shares

$249 Million
0.0% of portfolio
Wellington Management Group LLP Boston, MA

9.85M
Shares

$204 Million
0.04% of portfolio
Capital Research Global Investors Los Angeles, CA

5.48M
Shares

$114 Million
0.02% of portfolio

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.78B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account